Asset Details
Do you wish to reserve the book?
Experimental Treatment of Ebola Virus Disease with Brincidofovir
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Experimental Treatment of Ebola Virus Disease with Brincidofovir
Do you wish to request the book?
Experimental Treatment of Ebola Virus Disease with Brincidofovir
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Experimental Treatment of Ebola Virus Disease with Brincidofovir
2016
Overview
The nucleotide analogue brincidofovir was developed to prevent and treat infections caused by double-stranded DNA viruses. Based on in vitro data suggesting an antiviral effect against Ebola virus, brincidofovir was included in the World Health Organisation list of agents that should be prioritised for clinical evaluation in patients with Ebola virus disease (EVD) during the West African epidemic.
In this single-arm phase 2 trial conducted in Liberia, patients with laboratory-confirmed EVD (two months of age or older, enrolment bodyweight ≥50 kg) received oral brincidofovir 200 mg as a loading dose on day 0, followed by 100 mg brincidofovir on days 3, 7, 10, and 14. Bodyweight-adjusted dosing was used for patients weighing <50 kg at enrolment. The primary outcome was survival at Day 14 after the first dose of brincidofovir. Four patients were enrolled between 01 January 2015 and 31 January 2015. The trial was stopped following the decision by the manufacturer to terminate their program of development of brincidofovir for EVD. No Serious Adverse Reactions or Suspected Unexpected Serious Adverse Reactions were identified. All enrolled subjects died of an illness consistent with EVD.
Due to the small sample size it was not possible to determine the efficacy of brincidofovir for the treatment of EVD. The premature termination of the trial highlights the need to establish better practices for preclinical in-vitro and animal screening of therapeutics for potentially emerging epidemic infectious diseases prior to their use in patients.
Pan African Clinical Trials Registry PACTR201411000939962.
Publisher
Public Library of Science,Public Library of Science (PLoS)
Subject
/ Adult
/ Antiviral Agents - pharmacology
/ Antiviral Agents - therapeutic use
/ Cytosine - analogs & derivatives
/ DNA
/ Female
/ Hemorrhagic Fever, Ebola - drug therapy
/ Hemorrhagic Fever, Ebola - virology
/ Humans
/ Liberia
/ Male
/ Medicine
/ Medicine and Health Sciences
/ Organophosphonates - pharmacology
/ Organophosphonates - therapeutic use
/ Patients
/ Research and analysis methods
/ Smallpox
/ Viruses
